TFC Therapeutics, a new ARCH Venture Partners biotech, on Thursday unveiled a mission to thwart the return of cancer and its spread to other parts of the body with new biologics.
The early-stage New York startup builds off four decades of cancer research out of Columbia University medical professor Azra Raza.
TFC has the exclusive license to develop a drug discovery platform targeting tumor macrophage hybrid, or TMH, cells based on work out of Raza’s lab alongside principal scientist and assistant professor Abdullah Ali. Raza directs the MDS Center at Columbia and has led research on myelodysplastic syndrome, various leukemias and other cancers across a career spanning Rush University, the University of Massachusetts and elsewhere before moving to her current base in 2010.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.